

April 8, 2020



## CHRS Position Statement Regarding Procedure Prioritization During the COVID-19 Pandemic

---

Matthew Bennett, MD, Vancouver, BC  
Blandine Mondésert, MD, Montreal, QC  
Ratika Parkash, MD, Halifax, NS  
Eugene Crystal, MD, Toronto, ON  
John Sapp, MD, Halifax, NS

### **The importance of procedure prioritization**

The recent COVID-19 pandemic has increased strain on healthcare resources. There is a need to reduce hospital occupancy and preserve essential medical material and equipment in anticipation of an oncoming high volume of patients with COVID-19, as well as concern that patients and care providers will be exposed to risk of contracting COVID-19 at the time of medical procedures.

These factors highlight the importance of procedure prioritization. Medical procedure prioritization is complex and based on many patient-, hospital- and community-specific factors. In a pandemic, many crucial variables — infection rates, risk of inoculation of medical staff and patients at the time of a procedure and the expected time until these risks peak and return to a lower risk — can only be estimated.

The individual mortality reduction associated with a procedure needs to be balanced with the population and individual risk of exposure associated with hospital utilization. Furthermore, medical staff infection may have downstream mortality effects due to the inability to treat subsequent patients. Procedure-associated morbidity reduction must be incorporated into procedural prioritization. Procedures that would otherwise only prevent hospitalization and emergency room visits now would reduce the mortality that may be incurred due to COVID-19 inoculation during a preventable hospital visit. Hospital-specific factors such as the need for medical staff or medical equipment need to be considered.

### **Guidance on procedure prioritization**

This document provides procedural prioritization guidance to clinicians treating patients with common heart rhythm disorders. Although these procedures have been categorized based on the degree of restriction of arrhythmia services, we acknowledge that many factors may impact the clinical decision to perform or postpone a procedure. Unanticipated situations and individual patient exigencies may warrant divergence from these suggestions — this document is intended as a reference that does not supersede, but rather complements, clinical judgement.

We encourage clinicians and researchers to track cardiovascular outcomes relevant to these recommendations. Such efforts may prompt changes to these recommendations or inform future decision making should similar situations arise in the future.

At all times, patient screening for COVID-19 and proper personal protective equipment (PPE) utilization is recommended in accordance with current public health recommendations. It may be helpful to have a local group prioritize patient procedures when there are limited resources and multiple patients needing care.

<b>Procedure*</b>	<b>Moderate restriction in regular services</b>	<b>Severe restriction in regular services</b>
<b>Diagnostic EP study</b>	Patients with syncope who are perceived to be at high risk	Defer
<b>SVT ablation</b>	Drug-refractory SVT leading to incessant arrhythmia	Defer
<b>WPW/AP ablation</b>	<ul style="list-style-type: none"> <li>• Pre-excited AF,</li> <li>• cardiac arrest,</li> <li>• syncope, or</li> <li>• drug-refractory incessant arrhythmia</li> </ul>	AF with: <ul style="list-style-type: none"> <li>• very rapid pre-excited rate (shortest RR&lt;250 ms),</li> <li>• cardiac arrest,</li> <li>• syncope, or</li> <li>• drug-refractory incessant arrhythmia</li> </ul>
<b>PVC ablation</b>	Defer	Defer
<b>Idiopathic VT ablation</b>	Incessant drug-refractory VT	Incessant drug-refractory VT
<b>Scar-related VT ablation</b>	Recurrent or incessant, drug-refractory VT	Incessant, drug-refractory VT
<b>AF ablation, PVI</b>	Defer	Defer
<b>A flutter ablation</b>	Recurrent symptomatic, drug-refractory e.g. heart failure	Defer
<b>AV node ablation</b>	Drug refractory, highly symptomatic atrial arrhythmias	Defer
<b>Cardioversion</b>	Highly symptomatic arrhythmias with drug refractory rapid ventricular rates	Highly symptomatic arrhythmias with drug refractory rapid ventricular rates
<b>Primary prevention ICD implant</b>	Patients with high risk features (e.g. syncope, high-burden symptomatic NSVT)	Defer
<b>Secondary prevention ICD implant</b>	Appropriate	Appropriate
<b>CRTP/D</b>	NYHA III heart failure despite medical therapy in primary or secondary prevention	Patients requiring either: <ul style="list-style-type: none"> <li>• secondary prevention ICD implant or</li> <li>• emergency pacing</li> </ul>

Procedure*	Moderate restriction in regular services	Severe restriction in regular services
<b>Pacemaker implant</b>	<ul style="list-style-type: none"> <li>• Symptomatic Mobitz II Second Degree AV block (or worse) or</li> <li>• high-grade AV block or worse or</li> <li>• severe symptomatic sinus node dysfunction</li> </ul>	<ul style="list-style-type: none"> <li>• Life-threatening AV block or</li> <li>• life-threatening sinus node dysfunction</li> </ul>
<b>Pacemaker/CRT-P gen change/revision**</b>	Patients at ERI who are: <ul style="list-style-type: none"> <li>• pacemaker-dependent*** or</li> <li>• CRT dependent</li> </ul>	Patients who are approaching end-of-service who are pacemaker dependent***
<b>ICD/CRT-D gen change</b>	Patients who are at ERI who are: <ul style="list-style-type: none"> <li>• pacing or</li> <li>• CRT dependent or</li> <li>• who have had prior appropriate tachy therapy or</li> <li>• for whom implant is for secondary prophylaxis or</li> <li>• device malfunction</li> </ul>	Patients who are approaching end of service who are: <ul style="list-style-type: none"> <li>• pacing/CRT-dependent</li> <li>• recent appropriate tachy therapy</li> </ul>
<b>Lead replacement/revision**</b>	Leads at high risk for loss of function in patients who: <ul style="list-style-type: none"> <li>• are pacing-dependent, or</li> <li>• have secondary prophylaxis ICD</li> </ul>	Leads at high risk for loss of function in patients who: <ul style="list-style-type: none"> <li>• are pacing-dependent or</li> <li>• have secondary prophylaxis ICD</li> </ul>
<b>Lead extraction</b>	Appropriate for device infection	Appropriate for device infection with: <ul style="list-style-type: none"> <li>• endocarditis, or</li> <li>• intracardiac prosthetic device</li> </ul>
<b>ILR implant</b>	Patients with syncope perceived to be at high risk	<b>Defer</b>
<b>Tilt-table testing</b>	<b>Defer</b>	<b>Defer</b>
<b>LAA closure</b>	<b>Defer</b>	<b>Defer</b>

\* We assume that all patients meet published guidelines regarding procedural appropriateness.

\*\* The urgency of device system revision refers to revising the component of the device system associated with a significant morbidity or mortality benefit or when deferring the revision will make the component non-revisable.

\*\*\* Patients are deemed to be pacemaker dependent if hemodynamically significant bradyarrhythmias are likely to occur in the absence of a pacemaker.

CHRS Device Committee	CHRS Ablation Committee
<ul style="list-style-type: none"> <li>• Dr. Jason Andrade</li> <li>• Dr. Derek Exner</li> <li>• Dr. Clarence Khoo</li> <li>• Dr. Ratika Parkash</li> <li>• Dr. Francois Philippon</li> <li>• Dr. Calum Redpath</li> <li>• Dr. Raymond Yee</li> </ul>	<ul style="list-style-type: none"> <li>• Dr. Laurent Macle</li> <li>• Dr. Gary Amit</li> <li>• Dr. Vijay Chauhan</li> <li>• Dr. Eugene Crystal</li> <li>• Dr. Marc Dyell</li> <li>• Dr. Benedict Glover</li> <li>• Dr. Girish Nair</li> <li>• Dr. Ratika Parkash</li> <li>• Steve Klassen</li> </ul>

